Pertussis vaccination in pregnancy - current data on safety and effectiveness

Area of Science:

• Infectious Diseases
• Pediatrics
• Public Health

Background:

• Whooping cough (pertussis), caused by Bordetella pertussis/parapertussis, is a WHO-identified poorly controlled respiratory infection.
• Early symptoms are nonspecific, complicating diagnosis, while severe cases present with characteristic inspiratory 'whoop,' cough, and vomiting.
• Pertussis significantly impacts children (0-4 years) and adolescents/seniors, with high hospitalization, morbidity, and mortality rates in infants.

Purpose of the Study:

• To highlight the effectiveness and safety of maternal pertussis vaccination for infant protection.
• To emphasize the public health recommendation for Tdap vaccination during pregnancy.

Main Methods:

• Review of pertussis epidemiology and clinical presentation.
• Analysis of maternal vaccination benefits for infant immunity.
• Inclusion of Advisory Committee on Immunization Practices (ACIP) recommendations.

Main Results:

• Maternal pertussis vaccination provides approximately 90% protection to infants in their first two months of life.
• This vaccination strategy is safe for both pregnant women and their infants.
• ACIP recommends Tdap vaccination for pregnant women between 27-36 weeks gestation.

Conclusions:

• Maternal immunization is a highly effective method for preventing pertussis in vulnerable infants.
• Routine Tdap vaccination during pregnancy is a critical public health intervention.